Here is the synopsis of our sample research paper on General Electric Medical Systems and the Future of MRI. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 5 page paper provides an overview of the company's strategy, its alliances and its targeting of MRI technology. MRI and possible future enhancements are evaluated. Recommendations are provided. Bibliography lists 4 sources.
Page Count:
5 pages (~225 words per page)
File: RT13_SA215MRI.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
revolutionize medicine in the future. With the innovations such as ultrasound, and MRI, people no longer have to undergo invasive procedures, or even surgery, in order to come up with
a diagnosis in some cases. Today, technology does allow doctors to see beneath the skins surface and look at organs on a screen. Such things are not the future,
but something that is occurring presently. Of course, these innovations are not always available to every person due to the high cost of new technology. It does help to predict
the wave of the future where such noninvasive procedures will be cost-effective and provide availability to most everyone in the United States. General Electric Medical Systems is one company that
seems to be making strides in the area of affordability. United States diagnostic equipment manufacturer General Electric Medical Systems had aligned itself with Epix Medical Inc. and Vital Imaging
Systems Inc. to form a network that will have the ability to develop and market cardiovascular imaging products and technology (Henderson, 2000). The potential of magnetic resonance imaging (MRI)
to revolutionize clinical practice should be seen as the offering of a cost-effective way to diagnose vascular disease, and is remarkable (2000). MRI in fact does have the potential
to revolutionize clinical practice through the offering of such a way and important hardware, software, and product developers in the field have described the effect of AngioMARK (MS-325), which
is essentially Epixs lead contrast agent developed along with Mallinckrodt, Inc. (2000). In creating non-invasive diagnosis and management of cardiovascular disease, such innovations will be quite marketable (2000).
General Electric Medical Systems along with EPIX and VTAL have in fact formed an innovative network that helps one to develop and market the new generation of non-invasive, cost effective
...